Actor Jeff Bridges Shares Lymphoma Diagnosis
Title: Actor Jeff Bridges Shares Lymphoma DiagnosisCategory: Health NewsCreated: 10/20/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 21, 2020 Category: Cancer & Oncology Source Type: news

Actor Jeff Bridges Shares Lymphoma Diagnosis
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 20, 2020 Category: Cancer & Oncology Tags: Nursing, Oncology, News, Source Type: news

Actor Jeff Bridges Shares Lymphoma Diagnosis
TUESDAY, Oct. 20, 2020 -- Actor Jeff Bridges announced on Monday that he has been diagnosed with lymphoma. Telling his fans on Twitter, the acclaimed thespian said, " Although it is a serious disease, I feel fortunate that I have a great team of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 20, 2020 Category: General Medicine Source Type: news

Actor Jeff Bridges being treated for lymphoma
Famous for his role of The Dude in The Big Lebowski, Bridges says the disease is serious but his prognosis is good (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Jeff Bridges announces he was diagnosed with lymphoma
The actor made the announcement on Twitter Monday. (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

FX & ‘The Old Man’ Producers React To Jeff Bridges’ Lymphoma Diagnosis: “We Are All In This Together With You”
Jeff Bridges, who this evening revealed that he has been diagnosed with lymphoma, has been filming FX on Hulu’s The Old Man in his... (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Jeff Bridges says he's been diagnosed with lymphoma
The Oscar-winning actor said he's starting treatment and the "prognosis is good." (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Jeff Bridges Announces Lymphoma Diagnosis
Actor Jeff Bridges announced on Twitter Monday afternoon that he has been diagnosed with lymphoma. He started his post off with a... (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines
The diagnosis of pediatric Hodgkin lymphoma requires an excisional or incisional biopsy and immunohistochemistry (IHC) evaluation, and its management depends largely on the clinical stage and risk group, according to new guidelines from the National Comprehensive Cancer Network (NCCN).Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 19, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
Brexucabtagene autoleucel (Tecartus) is a new cell therapy product and the only one with an indication for this particular hematological malignancy.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA extends approval of pembrolizumab for classical Hodgkin lymphoma
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
(American Association for Cancer Research) The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 14, 2020 Category: Cancer & Oncology Source Type: news

Relationship Explored Between Physical Activity and Lymphoma
TUESDAY, Oct. 13, 2020 -- High levels of physical activity may lower the risk for developing lymphoma, according to a review/meta-analysis published online Oct. 6 in BMC Cancer. Gwynivere A. Davies, M.D., M.P.H., from the Juravinski Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 13, 2020 Category: Pharmaceuticals Source Type: news

Anticancer compounds for B cell cancer therapy targeting cellular stress response
(The Wistar Institute) Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2020 Category: Biology Source Type: news

New radioimmunotherapy improves lymphoma treatment
Researchers have found that a new radioimmunotherapy can reverse resistance...Read more on AuntMinnie.comRelated Reading: New radiotracer increases multiple myeloma survival PET/CT pinpoints Hodgkin's lymphoma treatment response PET rules out need for radiotherapy in lymphoma patients Radioimmunotherapy shows promise for curing HIV infection SNMMI touts radioimmunotherapy study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 9, 2020 Category: Radiology Source Type: news

Latest T-Cell Clinical Trial Opens for Mesothelioma Patients
Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy. This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the la...
Source: Asbestos and Mesothelioma News - October 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news

7 Things to Know About New Lymphoma Drug Tafasitamab 7 Things to Know About New Lymphoma Drug Tafasitamab
Lymphoma specialist Ann LaCasce, MD, discusses tafasitamab-cxix, the recently approved treatment for patients with relapsed/refractory disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in in patients with large B-cell lymphoma
(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2020 Category: Cancer & Oncology Source Type: news

FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

Adding polatuzumab vedotin cost effective in large B-cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2020 Category: Drugs & Pharmacology Source Type: news

Economic and QOL evidence scarce in mantle cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2020 Category: Drugs & Pharmacology Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Maximizing cures and minimizing side effects in children with Hodgkin lymphoma
(National Comprehensive Cancer Network) The National Comprehensive Cancer Network (NCCN) announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma. Hodgkin lymphoma is one of the most curable forms of pediatric cancer, with long-term survival rates of 90% or higher . However, treatment can result in potentially life-threatening or -altering long-term side effects. These new recommendations from NCCN synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

Can Lymphoma Be Completely Cured?
Title: Can Lymphoma Be Completely Cured?Category: Diseases and ConditionsCreated: 9/24/2020 12:00:00 AMLast Editorial Review: 9/24/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 24, 2020 Category: Cancer & Oncology Source Type: news

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
LAUSANNE, Switzerland--(BUSINESS WIRE)-- September 24, 2020 -- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 24, 2020 Category: Drugs & Pharmacology Source Type: news

Penn researchers discover potential cause of immunotherapy-related neurotoxicity
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

Stop Livin to make lymphoma cells stop living
(University of Tsukuba) Researchers at the University of Tsukuba have shown that the protein Livin, an inhibitor of apoptosis or programmed cell death, mediates resistance to immunotherapy in some lymphoma variants. Therapeutically targeting Livin with IAP inhibitors or BET inhibitors may provide a practical strategy for patients with Livin-positive and other refractory B-cell lymphomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 16, 2020 Category: Cancer & Oncology Source Type: news

The Josep Carreras Institute identifies a marker of poor evolution in Hodgkin's lymphoma
(Josep Carreras Leukaemia Research Institute) Dr. Manel Esteller, director of the Josep Carreras Leukemia Research Institute, published today in Blood journal, the discovery of a marker that allows predicting which patient with Hodgkin's lymphoma will present the aggressive clinical course, and will therefore be a case of special risk. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Causes of Lymphoma and Its Action in the Body
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 11, 2020 Category: General Medicine Source Type: news

Mantle Cell Lymphoma: Identifying Patients With Indolent Disease Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
Biomarkers are key in distinguishing between high-risk and indolent cases, allowing the latter to avoid unnecessary initial treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mechanisms of autoregulation of C3G, activator of the GTPase Rap1, and its catalytic deregulation in lymphomas
C3G is a guanine nucleotide exchange factor (GEF) that regulates cell adhesion and migration by activating the GTPase Rap1. The GEF activity of C3G is stimulated by the adaptor proteins Crk and CrkL and by tyrosine phosphorylation. Here, we uncovered mechanisms of C3G autoinhibition and activation. Specifically, we found that two intramolecular interactions regulate the activity of C3G. First, an autoinhibitory region (AIR) within the central domain of C3G binds to and blocks the catalytic Cdc25H domain. Second, the binding of the protein’s N-terminal domain to its Ras exchanger motif (REM) is required for its GEF ac...
Source: Signal Transduction Knowledge Environment - August 31, 2020 Category: Science Authors: Carabias, A., Gomez-Hernandez, M., de Cima, S., Rodriguez-Blazquez, A., Moran-Vaquero, A., Gonzalez-Saenz, P., Guerrero, C., de Pereda, J. M. Tags: STKE Research Articles Source Type: news

Non-Hodgkin's Lymphoma
Title: Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/31/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 31, 2020 Category: Cancer & Oncology Source Type: news

Watchful Waiting Urged for Indolent Lymphoma During COVID-19 Watchful Waiting Urged for Indolent Lymphoma During COVID-19
The threshold for treatment initiation during the COVID-19 pandemic should be high for patients with indolent lymphomas, the American Society of Hematology advises.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

PET/CT could be useful for diagnosing fever
F-18 FDG PET/CT could be an effective tool for evaluating unexplained fevers...Read more on AuntMinnie.comRelated Reading: SNMMI 2020: PSMA-PET/CT changes prostate cancer management SNMMI 2020: PET tracer could image, treat glioblastoma PET/CT confirms breast cancer predicted by blood markers New PET/CT tracer reliably detects prostate cancer PET/CT pinpoints Hodgkin's lymphoma treatment response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 27, 2020 Category: Radiology Source Type: news

Experiences With Cancer, Captured in Works of Art
The program Brushes With Cancer pairs patients with artists whose works make visible a disease that can be invisible and isolating. (Source: NYT Health)
Source: NYT Health - August 26, 2020 Category: Consumer Health News Authors: Susan Gubar Tags: Art Breast Cancer Hodgkin ' s Lymphoma Ovarian Cancer Coronavirus (2019-nCoV) Source Type: news

NICE recommends combination treatment for some lymphoma patients
Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE. (Source: NHS Networks)
Source: NHS Networks - August 20, 2020 Category: UK Health Source Type: news

Dramatic Radiotherapy Response in a Necrotic Lymphoma Mass Dramatic Radiotherapy Response in a Necrotic Lymphoma Mass
This case illustrates the potential for single modality palliative radiotherapy to reduce disease burden in patients with diffuse large B-cell lymphoma who are not fit for systemic therapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

The behavior of therapeutic antibodies in immunotherapy
(CNRS) Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the more than 20 years since their use began, the molecular mechanisms that underlie this therapy are still little understood. For the first time, scientists from the CNRS, Institut Pasteur and Universit é de Bordeaux have observed the interaction between therapeutic antibodies and their target protein. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 13, 2020 Category: Cancer & Oncology Source Type: news

TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 13, 2020 Category: Drugs & Pharmacology Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves New Drug for Diffuse Large B-Cell Lymphoma FDA Approves New Drug for Diffuse Large B-Cell Lymphoma
A novel drug that targets CD19 has been approved for use with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma
Oncology news burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
PLANEGG/MUNICH, Germany - August 1, 2020 and WILMINGTON, Del. - July 31, 2020 MorphoSys AG NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

First U.S. Dog With COVID-19 Has Died
Whether the dog died from the coronavirus or lymphoma isn't clear. Buddy got sick in April but it wasn't until May that a vet confirmed the animal was infected. (Source: WebMD Health)
Source: WebMD Health - July 31, 2020 Category: Consumer Health News Source Type: news

Few U.S. Women Know About Cancer That Develops Near Breast Implants: Study
THURSDAY, July 30, 2020 -- There's a low level of awareness among American women about a form of lymphoma that can occur around breast implants, a new study finds. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an immune... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 30, 2020 Category: General Medicine Source Type: news

Mayo Clinic Q and A: New blood cancer treatment options with chimeric antigen receptor-T cell therapy
Dear Mayo Clinic: My brother was diagnosed with non-Hodgkin lymphoma a few years ago and has had several recurrences. I was reading about something called chimeric antigen receptor-T cell therapy (CAR-T cell therapy) and was wondering how it works and if he might be a candidate for it? Answer: CAR-T cell therapy is a relatively new treatment that [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 29, 2020 Category: Databases & Libraries Source Type: news